Somewhat Favorable News Coverage Somewhat Unlikely to Affect Covidien (COV) Stock Price

Headlines about Covidien (NYSE:COV) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Covidien earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned media coverage about the healthcare company an impact score of 46.1795881481897 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Shares of Covidien (NYSE:COV) remained flat at $$106.71 during trading hours on Wednesday. Covidien has a twelve month low of $65.97 and a twelve month high of $108.57. The firm has a market capitalization of $48,980.00, a PE ratio of 27.43 and a beta of 1.01.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Covidien (COV) Stock Price” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.com-unik.info/2018/01/10/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-covidien-cov-stock-price.html.

Covidien Company Profile

Covidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company’s brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries.

Insider Buying and Selling by Quarter for Covidien (NYSE:COV)

Receive News & Ratings for Covidien Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covidien and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit